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Abstract: The expectations of nanoparticle (NP)-based targeted drug delivery systems in cancer, 
when compared with convectional therapeutic methods, are greater efficacy and reduced drug 
side effects due to specific cellular-level interactions. However, there are conflicting literature 
reports on enhanced tumor accumulation of targeted NPs, which is essential for translating their 
applications as improved drug-delivery systems and contrast agents in cancer imaging. In this 
study, we characterized biodegradable NPs conjugated with an anti-CD20 antibody for in vivo 
imaging and drug delivery onto tumor cells. NPs’ binding specificity mediated by anti-CD20 
antibody was evaluated on MEC1 cells and chronic lymphocytic leukemia patients’ cells. The 
whole-body distribution of untargeted NPs and anti-CD20 NPs were compared by time-domain 
optical imaging in a localized human/mouse model of B-cell malignancy. These studies provided 
evidence that NPs’ functionalization by an anti-CD20 antibody improves tumor pharmacoki-
netic profiles in vivo after systemic administration and increases in vivo imaging of tumor 
mass compared to non-targeted NPs. Together, drug delivery and imaging probe represents a 
promising theranostics tool for targeting B-cell malignancies.
Keywords: active targeting, optical imaging, tumor accumulation
Introduction
Nanomedicine for cancer therapy is advantageous over conventional medicine1 because 
it has the potential to enable the preferential delivery of drugs to tumors owing to the 
enhanced permeability and retention (EPR) effect, and the delivery of more than one 
therapeutic agent for combination therapy.2 Moreover, the engineering of a targeting 
ligand onto the nanoparticles’ (NPs’) surface can result in prolonged and localized drug 
delivery, which should translate into greater efficacy and reduced drug side effects.3–5
Cancer treatment stands to benefit from targeted drug delivery, as tumor cells 
express many molecules on their surface that distinguish them from normal cells.6 
Although there are expectations of improved efficacy of targeted NPs derived from 
specific cellular-level interactions, there are conflicting literature reports on tumor 
accumulation of targeted NPs: previous reports suggest that a tumor-targeting ligand 
does not increase NP accumulation in tumors, but the targeting antibody may increase 
tumor cell internalization.3,7 The results of these studies suggest that the tumor local-
ization of NPs is independent of the ligand and primarily relies on the EPR effect.8 
These reports are in contrast, however, to others, which suggest that the attachment 
of tumor-targeting antibody on NPs enhances total accumulation in solid tumor.9–11 
One difference might be the presence or absence of polyethylene glycol (PEG) in the 
complex and its impact on the EPR effect.12 In fact, the increased circulation time 
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and tumor retention time of the PEGylated complexes could 
result in the enhanced tumor accumulation of both targeted 
and untargeted complexes, thereby masking any effect of the 
ligand in the process. EPR is a highly variable phenomenon, 
characterized by large inter- and intraindividual differences. 
In light of this, a significant number of tumor-targeting stud-
ies have focused on the evaluation of parameters affecting 
the EPR effect,13,14 and additional studies are clearly needed 
to understand the influence of NPs’ modification on tumor 
localization and uptake.3,7,9–11
Currently, several nanotechnology-enabled diagnostic 
and therapeutic agents for cancer are in clinical trials.15 
Indeed, multifunctionality is the key feature of NP-based 
agents. Targeting ligands, imaging labels, therapeutic drugs, 
and other functionalities can all be integrated to allow for tar-
geted molecular imaging and cancer molecular therapy.16
Recently, we focused on identifying “next-generation” 
treatments for B-cell disorders17,18 that currently take advantage 
of dose-intensive chemotherapy regimens and immunotherapy 
via use of monoclonal antibodies. We developed a novel 
therapeutic approach based on hydroxychloroquine- and 
chlorambucil-loaded anti-CD20 NPs, which selectively inhibits 
tumor growth in mice bearing B-cell lymphoma xenograft.
In this work, the whole-body distribution of Cy5.5- 
untargeted NPs and Cy5.5-anti-CD20 NPs was determined 
by time-domain (TD) optical imaging (OI) in a localized 
animal model of B-cell malignancy, thus providing insight for 
the NP behavior in vivo as imaging probe. Our studies provide 
evidence that NPs’ functionalization by an anti-CD20 ligand 
and imaging agent improves tumor pharmacokinetic profiles 
in vivo after systemic administration and represent a promis-
ing imaging tool for the diagnosis of B-cell malignancies.
Material and methods
synthesis and characterization of NPs
Chemicals used for NP preparation were reagent grade or 
better. Some of the purchased chemicals included polyeth-
ylene glycol (PEG Nektar, San Carlos, CA, USA) Hydroxy-
chloroquine sulfate (HCQ, ACROS, Gel, Belgium) and 
Chlorambucil (CLB, Sigma Aldrich, St Louis, MO). NPs 
based on carboxylic acid-terminated biodegradable polymers 
(PLA-b-PEG-COOH and PCL-COOH) were produced with 
an expected average diameter of 250 nm. NPs were fabricated 
under class 100 clean-room conditions using a proprietary 
electrohydrodynamic technology (Bio-Target Inc., Chigaco, 
IL, USA; LNK Chemsolutions LLC, Lincoln, Nebraska, 
USA). Briefly, for all NP formulations, organic solutions con-
taining all the necessary components were processed using 
this technology resulting in a dry collection of the specified 
NPs. The collected material was then harvested in an aqueous 
buffer solution to obtain a stable suspension.18 NPs were 
suspended in 0.1 M sodium carbonate buffer (pH =9.3) 
and stained with FluoroLink™ Cy5.5 Monofunctional Dye 
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) for 30 
minutes. To eliminate the excess of dye, NPs were dialyzed. 
The amount of Cy5.5 associated with the NP surface was 
quantified by spectrophotometric methods. Molar extinction 
coefficients of 250,000 M-1 cm-1 at 678 nm for the Cy5.5 
dye were used.
NPs’ hydrodynamic diameter (d
H
) distributions and 
ζ-potential values were determined using a Malvern Nano 
ZS instrument as previously described.19
Mec1 and chronic lymphocytic leukemia 
cell microscopy
MEC1 cell line (kindly provided by Professor Josee Golay) 
was cultured in RPMI-1640 medium (Sigma-Aldrich Co., 
St Louis, MO, USA) supplemented with 10% fetal bovine 
serum (Thermo Fisher Scientific, Waltham, MA, USA). 
Heparinized peripheral blood samples were obtained after 
informed consent from eight B-chronic lymphocytic leukemia 
(CLL)-untreated patients characterized as such in Table S1, and 
the mononuclear cell fractions were isolated by centrifugation 
on Ficoll-Hypaque (GE Healthcare) density gradients.20 For 
fluorescence staining, MEC1 cells and CLL-patients’ cells 
were suspended in serum-free RPMI-1640 medium and stained 
with Vybrant™ DiI cell-labeling solution (GE Healthcare) for 
20 minutes. The excess of dye was eliminated by centrifugation. 
To label nuclei, MEC1 cells were stained with DAPI (Sigma-
Aldrich Co.) for 5 minutes. Finally, the samples were cytocen-
trifuged on positive-charged glasses (Bio-Optica, Milan, Italy) 
and analyzed using a Leica DM2000 fluorescence microscope 
(Leica Microsystems, Wetzlar, Germany). In addition, electron 
microscopy samples were treated as previously described by 
preparing ultrathin sections with an Ultratome III (Pharmacia 
LKB, Uppsala, Sweden) which were analyzed by transmission 
electron microscopy (TEM) (EM208; Philips, Eindhoven, the 
Netherlands).21 Micrographs were acquired with a Morada 
Camera (Olympus Corporation, Tokyo, Japan).
Flow cytometric analysis
The immunophenotypical characterization of MEC1 and 
CLL-affected patients’ cells was made by incubating 5×105 
cells with anti-human CD45 fluorescein isothiocyanate 
(FITC) (ImmunoTools, GmbH, Friesoythe, Germany), anti-
human CD5 PE (Phycoerythrin) (ImmunoTools), anti-human 
CD19 PE (ImmunoTools), or anti-CD79a PE (BD, Franklin 
Lakes, NJ, USA) monoclonal antibodies. To study CD20 
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expression, cells were incubated with the anti-CD20 chi-
meric monoclonal antibody rituximab (Hoffman-La Roche 
Ltd., Basel, Switzerland) derived from the clinic (University 
of Trieste, Trieste, Italy) and the anti-human IgG1 FITC 
(Sigma-Aldrich Co.) antibody. NPs’ binding was assayed 
after incubating MEC1 and CLL-patients’ cells with 20 μL of 
NPs for 1 hour at 37°C. Both experiments were analyzed by 
FACSCalibur (BD) flow cytometer and data were analyzed 
by CELLQuest software (BD).
Mice
Female SCID mice (4–6 weeks old) were purchased from 
Harlan (San Pietro Al Natisone, Udine, Italy) and maintained 
under pathogen-free conditions with ad libitum food and 
water, in accordance with the guide for the care and use of 
laboratory animals. Xenograft-bearing mice were established 
through subcutaneous (sc) injection on the left flank of 107 
MEC1 cells resuspended in 150 μL of phosphate-buffered 
saline. All the experimental procedures were performed in 
compliance with the guidelines of European and Italian laws 
and were approved by the institutional animal ethical care 
committee of the University of Trieste and by the Italian 
Ministry of Health.
In vivo and ex vivo OI
All in vivo data was acquired by using the small-animal TD 
Optix MX2 preclinical near-infrared (NIR) fluorescence-imager 
(Advanced Research Technologies, Montreal, Canada), 
equipped with a pulsed laser diode and a time-correlated 
single-photon counting detector, as previously described.22,23 
Briefly, mice were shaved prior to the scanning procedure in 
order to reduce scattering of the signal from hair. Throughout 
all imaging sessions, mice were anesthetized with vaporized 
isoflurane at 1.8%–2.0% volume (Biological Instruments, 
Besozzo VA, Italy). Two-dimensional regions of interest 
were selected, and laser power, integration time (repetition 
time of the excitation per raster point), and scan step size 
were optimized according to the emitted signal. The data were 
recorded as temporal point-spread functions and the images 
were reconstructed as fluorescence intensity maps. Prior to 
injection of the NPs, mice were scanned to obtain background 
images. For ex vivo OI, the last in vivo whole-body imaging 
session was followed by euthanasia of animals. The organs 
were explanted and imaged with the same Optix system.24
Tumor tissue analyses
For each mouse (n=6), tumor size was assessed thrice per 
week by caliper measurement. Tumor volume was calculated 
as follows:
 Volume = D × d2 × π/6 (1)
where D and d are the longer and the shorter diameters, 
respectively. After ex vivo OI acquisitions, explanted 
organs and sc tumor masses were fixed in 10% buffered-
formalin solution and embedded in paraffin for histological 
analysis, or embedded in OCT (optimal cutting temperature) 
compound embedding medium (Miles, Inc., Diagnostics 
Division, Elkhart, IN, USA) and snap-frozen at -80°C for 
fluorescence microscopy. For confocal microscopy analysis, 
sections of 30 μm thickness were cut from frozen organs 
with a cryostat at -20°C and analyzed using confocal micro-
scope Eclipse te300 (Nikon Corporation, Tokyo, Japan). 
Immunohistochemical analysis of the tumoral masses were 
performed with hematoxylin and eosin to evaluate the tissue 
morphology, and with the avidin–biotin–peroxidase complex 
to localize CD5, CD20, CD45, and CD79a antigens.25 The 
slides were examined under a Leica DM2000 optical micro-
scope (Leica Microsystems).
statistical analysis
Results from at least three independent experiments are 
reported as the means ± standard deviation and analyzed for 
statistical significance by the unpaired Welch two-sample 
t-test. Differences were considered significant when P-value 
was 0.05.
Results
synthesis and characterization of NPs
Two different types of NPs, called untargeted NPs and anti-
CD20 NPs, were prepared. In detail, untargeted NPs were 
made only by PLA-b-PEG-COOH and PCL-COOH as poly-
meric carriers, and anti-CD20 NPs were prepared conjugating 
the anti-CD20 chimeric antibody rituximab on the surface 
of untargeted NPs. Morphological characterization by TEM 
images (Table 1) indicated a core diameter of 110±40 nm 
for untargeted NPs and a core diameter of 90±30 nm for 
Table 1 size distribution and surface potential characterization 
of NPs
Untargeted  
NPs
Anti-CD20 
NPs
dcore ± sD (nm) 110±40 90±30
hydrodynamic diametera ± sDb  
(PdI) (nm)c
190±60  
(0.58)
230±70  
(0.57)
ζ-potential ± sD (mV)c -7.8±0.9 -6.0±0.6
ζ-potential ± sD (mV)d -13.7±0.7 -10.5±0.5 
Notes: aNumber mean intensity diameter. bn=15. cIn PBs 1×, ph 7.4, Bsa 0.3%. 
dIn PBs 1×, ph 7.4, Bsa 0.3%, Kcl 1 mM.
Abbreviations: dcore, core diameter; NPs, nanoparticles; PBs, phosphate-buffered 
saline; PdI, polydispersity index; sD, standard deviation; Bsa, bovine serum albumin.
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Figure 1 Mec1 cells’ characterization and NPs’ binding.
Notes: (A) cells (5×105) were incubated with Pe-conjugated anti-cD5 or anti-cD79a and FITc-conjugated anti-cD19 and anti-cD45 antibodies. The expression of cD20 
on the surface of cells was confirmed using an anti-CD20 primary antibody (rituximab) and a FITC-conjugated antihuman secondary antibody. Samples were analyzed 
by FACSCalibur flow cytometer and data were analyzed by CELLQuest software. (B) FITC-conjugated NPs (green fluorescence) and cells labeled with Fast-DiI (red 
fluorescence) were incubated for 1 hour. DAPI was used to label nuclei (blue fluorescence). Samples were analyzed by cytometric analysis and with a Leica DM2000 optical 
microscope. Original magnification 630×.
Abbreviations: FITC, fluorescein isothiocyanate; FL1-H, green fluorescence, 530/30 nm bandpass filter; FL2-H, orange fluorescence, 585/42 nm bandpass filter; FSC-H, 
forward scatter height; M1, Marker 1; NP, nanoparticle; Pe, Phycoerythrin; ssc-h, side scatter height.
anti-CD20 NPs. The hydrodynamic diameter measured 
with dynamic light scattering (Table 1) was 190±60 nm for 
untargeted NPs, and 230±70 nm for anti-CD20 NPs, with a 
polydispersity index of 0.58 and 0.57, respectively, indicating 
a slight aggregation among particles.
The prepared NPs were suspended in phosphate-buff-
ered saline pH 7.4 to give a concentration of 1.66 mg/mL 
polymers, 8.8 μg/mL anti-CD20 antibody, and 2.8 nmol/mL 
Cy5.5.
characterization of Mec1 and NPs’ 
binding
MEC1 cells were characterized by evaluating the expres-
sion of surface antigens, such as CD5, CD19, CD20, CD45, 
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Figure 2 cll patients’ cell characterization and NP binding.
Notes: (A) cells 5×105 were incubated with Pe-conjugated anti-cD5 or anti-cD79a; and FITc-conjugated anti-cD19 and anti-cD45 antibodies. The expression of cD20 on 
the surface of cells was confirmed using an anti-CD20 primary antibody and a FITC-conjugated antihuman secondary antibody. Samples were analyzed by FACSCalibur flow 
cytometer and data were analyzed by CELLQuest software. (B) FITC-conjugated NPs (green fluorescence) and cells labeled with Fast-DiI (red fluorescence) were incubated 
for 1 hour at 37°C. NPs’ binding was evaluated by cytometric analysis. DAPI was used to label nuclei (blue fluorescence) and samples were analyzed with a Leica DM2000 
optical Microscope. Original magnification 100×.
Abbreviations: CLL, chronic lymphocytic leukemia; FITC, fluorescein isothiocyanate; FL1-H, green fluorescence, 530/30  nm bandpass filter; FL2-H, orange fluorescence, 
585/42 nm bandpass filter; M1, Marker 1; NP, nanoparticle; PE, Phycoerythrin; SSC-H, side scatter height.
and CD79a, by flow cytometry. The results showed that 
more than 90% of cells expressed CD19, CD20, CD45, and 
CD79a on their surface (Figure 1A). On the contrary, MEC1 
cells did not express CD5, confirming the features of this 
cell line.26 To study NPs’ binding specificity mediated by 
anti-CD20 antibody, FITC-conjugated anti-CD20 NPs were 
added to MEC1 cells for 1 hour and their binding was evalu-
ated by cytometric analysis and fluorescence microscope. 
Under these conditions, targeted anti-CD20 NPs were able 
to target more than 90% of cells (Figure 1B). Targeted anti-
CD20 NPs binding to MEC1 cells were also confirmed by 
TEM analysis, which suggested NPs’ internalization in a 
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Figure 3 characterization of a localized model of B-cell malignancies.
Notes: (A) Mice (n=6) were injected subcutaneously with 107 Mec1 cells and dimension of tumor mass was measured thrice per week. (B) representative sections 
from subcutaneous masses stained with h/e, anti-cD5, anti-cD20, anti-cD45, and anti-cD79a monoclonal antibodies and 3,3′-diaminobenzidine chromogen. Original 
magnification 200×.
Abbreviation: h/e, hematoxylin and eosin.
process different from endocytosis because of the absence 
of endocytotic vesicles. Moreover, NPs accumulated in the 
cells in only 1 hour, releasing their content in the cytoplasm 
but not in the nucleus, as already seen in lymphoma cells.17
characterization of cll patients’ cells 
and NPs’ binding
The expression of CD5, CD19, CD20, CD45, and CD79a on 
the surface of CLL-affected patients’ cells was demonstrated 
by flow cytometry (Figure 2A). The results showed that more 
than 90% of cells express all the antigens on the cell surface, 
confirming CLL cells’ immunophenotyping features.27 NPs’ 
binding to leukemic cells was also evaluated by cytometric 
analysis: labeled with FITC, targeted anti-CD20 NPs were 
incubated with CLL cells for 1 hour at 37°C and the result 
showed NPs’ ability to bind to more than 90% of patients’ cells; 
these data were also confirmed by fluorescence microscope, 
evidencing the presence of targeted NPs in the cytoplasm of 
patients’ B-cells (Figure 2B). Characterization of patient’s cells 
is summarized in Supplementary material (Table S1).
Development of a localized B-cell 
disorder mouse model
To characterize NPs’ biodistribution pattern, we set up a 
localized model of human B-cell disorder injecting 107 MEC1 
cells sc in the flank of SCID mice. Tumor mass growth was 
measured thrice a week demonstrating its exponential growth 
(Figure 3A). Tumor mass was also analyzed by immunohis-
tochemical analysis with anti-CD20, anti-CD5, anti-CD45, 
and anti-CD79a antibodies showing MEC1 cells’ immunophe-
notyping features in vivo. In fact, MEC1-derived tumor mass 
was positive for the expression of CD20, CD45, and CD79a 
but the expression of CD5 was not detected (Figure 3B). In 
addition, immunohistochemical analysis on liver, spleen, 
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Figure 4 In vivo analysis.
Notes: (A) Biodistribution of cy5.5-anti-cD20 NPs (0.3 nmol cy5.5, 125 mg NPs) injected intravenously via the tail vein in a mouse model subcutaneously transplanted with 
the CLL cell line MEC1 (leukemic mouse model). Whole-body scan of a representative mouse in supine position is shown; fluorescence intensity images were acquired at the 
indicated time postinjection and are displayed in Nc. The circles enclose the tumors. (B) Whole-body fluorescence intensity distribution in a representative leukemic mouse 
24-hours postinjection of cy5.5-anti-cD20 NPs and cy5.5-untargeted NPs displayed in Nc. The circles enclose the tumors. (C) The signal level profile describing the wash 
in/wash out of cy5.5-anti-cD20 NPs and cy5.5-untargeted NPs from liver and tumor is reported. Data are expressed as means ± standard deviation of three independent 
experiments. *P0.05 between cy5.5-anti-cD20 NPs and cy5.5-untargeted NPs.
Abbreviations: cll, chronic lymphocytic leukemia; Nc, normalized counts; NP, nanoparticle.
kidney, heart, brain, spinal cord, and bone marrow showed that 
MEC1 injection led to the formation of just a localized tumor 
mass without colonizing other tissues (data not shown).
In vivo and ex vivo OI
As shown in Figure 4A, a few minutes after intravenous 
injection of 1 nmol Cy5.5-anti-CD20 NPs, a diffuse distribu-
tion was observed throughout the body of the mouse. The 
contrast between tumor and surrounding tissue increased 
slowly, and was significantly higher than pre-contrast within 
the first 24 hours after injection and decreased over time. At 
24 hours after injection, Cy5.5-anti-CD20 NPs allowed for 
clear delineation of the sc tumor tissue from the surround-
ing background tissue, leading to a signal-to-background 
ratio of approximately 7:1 (Figure 4B). Cy5.5-anti-CD20 
NPs yield improved signal-to-background ratios (7:1) in 
comparison to Cy5.5-untargeted NPs (3:1). Interestingly, 
in vivo comparison of Cy5.5-untargeted NPs (n=5) and 
Cy5.5-anti-CD20 NPs (n=5) showed a significant difference 
between the fluorescence intensity within the tumor site from 
24 hours until 96 hours after injection (Figure 4C), while 
the intensity in the liver appeared to be almost the same 
(24 hours postinjection: difference of ~13%, P=0.40) and 
with no obvious overall difference in the NPs’ uptake. The 
higher tumor targeting efficiency of Cy5.5-anti-CD20 NPs 
was further demonstrated by ex vivo analysis (Figure 5). The 
average fluorescence intensity over tumor tissues explanted 
at 168 hours after NPs administration showed a much higher 
levels of Cy5.5-anti-CD20 NPs than Cy5.5-untargeted NPs 
(difference 84%, P=0.0069).
The selective localization of NPs within liver and tumor 
masses at the microscopic level was performed by confocal 
microscopy. The analyses of tissue cryosections isolated 
from mice sacrificed at 168 hours after administration are 
shown in Figure 5C. According to the significantly higher 
ex vivo-specific fluorescence signal, tumor masses of mice 
injected with Cy5.5-anti-CD20 NPs showed NIR fluorescent 
spots, consistent with clusters of NPs, while negligible NIR 
fluorescence was observed from the tumor mass sections 
of mice injected with Cy5.5-untargeted NPs. Fluorescence 
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Figure 5 ex vivo analysis.
Notes: (A) ex vivo optical imaging of organs explanted at 168 hours after cy5.5-untargeted NPs or cy5.5-anti-cD20 NPs administration are shown – 1: tumor mass; 
2: kidney; 3: liver; 4: lung; 5: spleen. (B) Histogram representation of the average fluorescence intensity (NC) over tumor and liver tissues explanted at 168 hours after NP 
administration. *Difference 84%, P-value =0.0069; **difference 34%, P-value =0.0056. Data are expressed as means ± standard deviation of three independent experiments. 
(C) confocal microscopy images of explanted tumor mass’ and liver’s cryosections obtained from cy5.5-untargeted NP and cy5.5-anti-cD20 NP injections into mice. Tissue 
sections were also photographed through a green filter (FITC) to visualize background autofluorescence. Original magnification 600×.
Abbreviations: FITC, fluorescein isothiocyanate; NC, normalized counts; NP, nanoparticle.
microscopy of liver sections revealed a non-homogeneously 
distributed NIR fluorescence signal, consistent with the 
presence of the NPs. All the microscopic observations were 
consistent with the in vivo and ex vivo fluorescence mea-
surements. Ex vivo OI analysis of the explanted organs (ie, 
kidneys, heart, spleen, brain, lungs, stomach, intestine, liver) 
showed the preferential elimination of the NPs through the 
liver and a significant presence in the gastrointestinal tract 
(data not shown).
Discussion
We previously showed the impact of surface functionalization 
of biodegradable polymeric NPs on therapeutic efficacy in a 
Burkitt’s lymphoma model.17 Of note, hydroxychloroquine-/
chlorambucil-loaded NPs conjugated with an anti-CD20 
antibody demonstrated a successful enhanced antitumor 
efficacy in vivo with respect to untargeted NPs, despite their 
comparable in vitro cytotoxic effect. In fact, the treatment 
of mice bearing B-cell lymphoma xenograft with anti-CD20 
NPs selectively inhibited lymphoma growth due to the pres-
ence of the anti-CD20 targeting antibody. However, besides 
the enhanced therapeutic efficacy, there was no conclusive 
evidence supporting an increased tumor accumulation of 
targeted NPs.
In the present study, we were motivated to test whether this 
targeting strategy could provide in vivo tumor accumulation 
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of a fluorescent contrast agent, potentially enabling tumor 
imaging. For this purpose, we first demonstrated in vitro 
the ability of targeted anti-CD20 NPs to bind to CLL cells. 
In detail, anti-CD20 NPs were able to bind high-CD20-
expressing cells such as MEC1 (mean fluorescence intensity: 
285) as well as CLL-affected patients’ cells which showed 
lower CD20 expression (mean fluorescence intensity: 77). 
Hence, we postulate that our anti-CD20 NPs could be very 
effective as a selective imaging probe for CD20-expressing 
tumors, and even serve as a personalized treatment strategy, 
by determining the expression level of these receptors in indi-
vidual patients. As a proof of concept, we reported a specific 
internalization of anti-CD20 NPs by patients’ CLL cells over-
expressing CD20 receptor, thus confirming the importance of 
anti-CD20 antibody in the active targeting of NPs.
Then, we investigate the in vivo tumor-targeting proper-
ties of NP preparations in a localized murine model of B-cell 
malignancies. To establish a xenograft model, we focused 
on the biological characteristics of CLL cell line MEC1 cells 
and we tested their immunophenotypic profile by antigen 
evaluation, such as CD5, CD19, CD20, CD45, and CD79a, 
which are characteristics of MEC1 cells26 and are commonly 
used for the diagnosis of CLL. We investigated a model of 
sc injection of MEC1 in SCID mice. The results showed that 
a visible and well-localized tumor mass developed within a 
few weeks and recapitulated human tumor cell line culture 
in terms of cell morphology and immunohistochemical 
profile, offering a reasonable model for the study of local 
tumor uptake. However, these data are not in line with the 
finding that after the s.c. challenging of MEC1 in Rag-/- mice 
it was evident the formation of the tumor mass at the site 
of injection but also the development of a diffuse model of 
B-cell malignancy is evidenced.28 It is likely that the differ-
ent backgrounds of the animals, and the presence of active 
immune cells like macrophage, polymorphonuclear leuko-
cyte, and natural killer cells, prevented MEC1 distribution in 
other organs.29,30 Xenograft models were analyzed by TD OI 
after systemic Cy5.5-labeled NP administration. The results 
showed that the attachment of anti-CD20 tumor-targeting 
antibody on NPs significantly enhanced its total accumulation 
in tumors with respect to untargeted NPs. Region of interest 
analysis of the tumor site revealed intriguing differences in 
fluorescence contrast between untargeted- and anti-CD20 
NPs. These findings indicate that the improved efficacy of 
anti-CD20 NPs most likely results from both interaction at 
the cellular level and enhanced tumor accumulation.
Of note, the incorporation of Cy5.5 as OI contrast agent 
within anti-CD20 NPs allowed us to clearly visualize the 
tumor mass within 24 hours after intravenous injection, 
which is critical for the successful development of imag-
ing contrast nanoprobes. This provides evidence for the 
possible accumulation of these polymeric NPs to be used 
as a diagnostic probe in tumor microenvironment. These 
results also explain published and unpublished data about 
the efficacy of these polymeric NPs for drug delivery col-
lected by our group. There are evidences about the need for 
a targeting agent on NPs’ surface for an effective delivery 
of cytotoxic drugs and the cure of animal models of B-cell 
malignancies. Untargeted NPs were almost ineffective in the 
treatment different models of B-lymphoma and leukemia. 
This is probably not due to an enhance accumulation in the 
tumor microenvironment, but instead due to an increase in 
selective interaction between anti-CD20 NPs and tumor cell 
surface, and a possible increase in the loading of cytotoxic 
drug in tumor cell cytoplasm.
Anti-CD19 was also tested as an NP-targeting agent,31 
alone or in combination with anti-CD20 antibodies. CD20 
receptor was chosen as a molecular target because it is char-
acterized by an high expression on cell surface of mature 
and tumoral B-cells. In addition, CD20 receptor is stable 
and provided with an high affinity for  Rituximab. All these 
conditions suggested to focus on anti-CD20 NPs which result 
to be more efficient than untargeted NPs.
Furthermore, considering the capacity of these polymeric 
NPs to load not only chemotherapeutic drugs but also DNA 
vectors, miRNA, siRNA, and different probes, anti-CD20 
NPs might become a highly attractive drug-delivery and 
imaging platform for future cancer theranostics.
Conclusion
In conclusion, NPs targeting the human B lymphocyte 
marker CD20 provide a strategy which could be extended 
as a generalized approach to improve the in vivo imaging 
of tumor mass, and to visualize the therapeutic agent deliv-
ery site in a wide variety of other CD20-expressing B-cell 
malignancies.
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Table S1 characterization of patient’s cells
Code CD19 CD5 CD49d CD20 CD38 ZAP-70 TP53 M SF3B1 M MYD88 M NOTCH 
status
IGHV 
status
FISH  
status
RB1
Pt 1 89.4 99.5 99.1 96 99.2 0 0 na TrI12
Pt 2 90 99.9 1.3 99.4 0.5 12.5 0 0 0 UM Del11
Pt 3 89.6 99.5 0.8 91.6 8 3.2 0 0 0 UM Del13, Del11
Pt 4 55.6 83.7 39 99.3 40.3 12 0 0 na Del13 0
Pt 5 60.8 70.6 35.3 98.4 45.8 10 0 0 na NOrM
Pt 6 99 64.8 2.2 98.3 12.2 8.7 0 0 0 M Del13, Del17
Pt 7 94.7 97.4 32.3 99.2 15 1 0 0 M Del13 omo
Pt 8 64.8 91.2 97 92.3 26 10 0 0 0 0 M Del13 0
Notes: cD19, cD5, cD49d, cD20, cD38 expressions are reported as percentage of positive cells. NOTch status was determined by arMs-Pcr, conventional, and next-
generation sequencing. IGHV status was established according to conventional cut-off; μm, IghV unmutated, m, IghV mutated. FIsh status was determined according to 
Bray.32 Other parameter expression was determined as reported in gattei et al.33
Abbreviations: ARMS-PCR, Amplification Refractory Mutation System-Polymerase Chain Reaction; FISH, Fluorescence in situ hybridization; IGHV, Immunoglobulin heavy 
chain variable region genes; na, not available; M, mutated; UM, unmutated.
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